NasdaqGS:ASNDBiotechs
Assessing Ascendis Pharma (ASND) Valuation After FDA Accelerated Approval For YUVIWEL
Ascendis Pharma (NasdaqGS:ASND) is in focus after the U.S. FDA granted accelerated approval for YUVIWEL, a once weekly treatment for children with achondroplasia, along with a Rare Pediatric Disease Priority Review Voucher.
See our latest analysis for Ascendis Pharma.
The FDA approval, Rare Pediatric Disease Priority Review Voucher and upcoming conference appearance at the TD Cowen Health Care Conference come alongside a 1 year total shareholder return of 59.34% and a 3 month share price...